血栓通注射剂治疗急性脑梗死有效性及抗凝血指标的meta分析  

Meta-analysis on the efficacy and anticoagulation indexes of Xueshuantong Injection in the treatment of ACI

作　　者：冯慧 黄玉鹏 王梦瑶 严小青 黄建春[1] FENG Hui;HUANG Yupeng;WANG Mengyao;YAN Xiaoqing;HUANG Jianchun(Pharmaceutical College,Guangxi Medical University,Guangxi,Nanning 530021,China)

机构地区：[1]广西医科大学药学院,广西南宁530021

出　　处：《中国医药科学》2023年第8期59-62,66,共5页China Medicine And Pharmacy

摘　　要：目的评价血栓通注射剂治疗急性脑梗死(ACI)的临床疗效和安全性。方法检索电子数据库CNKI、万方、VIP、SinoMed、Cochrane Library、PubMed,筛选血栓通注射剂治疗ACI的随机对照试验(RCTs),数据库检索时间从建库至2022年10月21日。根据Cochrane Handbook 5.1评价标准和RevMan 5.3软件对最终纳入的研究进行meta分析。共纳入20项研究,试验组(血栓通注射剂+常规治疗)931例,对照组(常规治疗)912例。结果与对照组比较,试验组ACI患者的凝血酶原时间和活化部分凝血酶原时间延长,临床有效率升高,血小板和纤维蛋白原水平降低。验组常见不良反应为牙龈出血和轻微皮疹,均可耐受或停药后消失,未见严重不良反应。结论血栓通注射剂治疗ACI能改善抗凝血指标,提高临床有效率。但由于纳入的研究可能存在一定的偏倚,仍需多中心、大样本及双盲的RCTs加以验证。Objective To assess the clinical efficacy and safety of Xueshuantong Injection in the treatment of acute cerebral infarction(ACI).Methods The randomized controlled trials(RCTs)on Xueshuantong Injection for the treatment of ACI included in electronic databases China National Knowledge Internet(CNKI),Wanfang,VIP,SinoMed,Cochrane Library and PubMed from the date of database establishment to October 21,2022 were retrieved.meta-analysis of the screened RCTs was performed according to Cochrane Handbook 5.1 assessment criteria and RevMan 5.3 software.A total of 20 RCTs were included,with 931 patients in the experimental group(Xueshuantong Injection+conventional treatment)and 912 patients in the control group(conventional treatment).Results The prothrombin time and activated partial thromboplastin time were longer,clinical efficiency was higher,and platelet count and fibrinogen level were lower in the experimental group than in the control group.The common adverse reactions in the experimental group were gingival bleeding and mild rash,which could be tolerated or disappeared after drug withdrawal.No serious adverse reactions were observed.Conclusion Xueshuantong Injection can improve anticoagulation indexes and increase clinical efficiency for the treatment of ACI.However,due to the possible bias of the included RCTs,more multi-center and double-blind RCTs with large sample size are still required,so as to further validate its effects.

关 键 词：血栓通注射剂 急性脑梗死 META分析 疗效 

分 类 号：R743.3[医药卫生—神经病学与精神病学]